The grocery chain operator behind Stop & Shop, Giant, Hannaford, and Food Lion has agreed to pay $40 million to settle federal claims that its in-store pharmacies systematically overcharged Medicare, Medicaid, and TRICARE by reporting inflated prescription prices, pocketing higher reimbursements than the law allowed.
Ahold Delhaize USA Inc., headquartered in Quincy, Massachusetts, reached the settlement with the Department of Justice after a whistleblower, a former pharmacist at one of the company's Pennsylvania supermarkets, flagged the billing scheme. The DOJ announced the deal last week, as the New York Post reported.
The core allegation is straightforward: Ahold Delhaize pharmacies offered customers prescription savings programs with discounted drug prices, but when those pharmacies filed claims with federal healthcare programs, they reported the higher, pre-discount price as the "usual and customary" cost. Federal regulations require pharmacies to report the discounted price, the one customers actually paid, when submitting claims. By reporting the inflated figure, the pharmacies triggered larger government reimbursements.
In plain terms, taxpayers got billed at one rate while customers paid a lower one. The difference went to the company.
Of the $40 million settlement, roughly $32.9 million will go to the federal government. The remainder flows to state Medicaid programs that participated in the case. The DOJ did not specify which states are receiving funds or the exact breakdown.
Lawrence LaBenne, the former pharmacist who blew the whistle, will receive more than $6 million from the federal share. LaBenne worked at an Ahold Delhaize supermarket in Pennsylvania and filed the complaint that helped trigger the investigation.
The settlement represents a significant enforcement action against one of the largest grocery operators in the country. Ahold Delhaize runs thousands of stores across the eastern United States under its four major banners.
Brett A. Shumate, Assistant Attorney General of the DOJ's Civil Division, framed the case as a breach of a basic obligation. In a statement, Shumate said:
"Federal healthcare programs rely on pharmacies reporting accurate pricing information used in the applicable payment formulas. If pharmacies report inflated 'usual and customary' prices on claims to federal healthcare programs, the programs pay more than they should on those claims."
Troy Rivetti, U.S. Attorney for the Western District of Pennsylvania, was more pointed. His office co-led the settlement effort alongside the DOJ's Civil Division, Commercial Litigation Branch, and Fraud Section.
"Pharmacies are trusted with charging the contracted prescription prices to Medicare and Medicaid and not unfairly and unlawfully taking advantage of the government and the public. This settlement confirms that the United States will take all necessary steps to bring to justice dishonest pharmacies."
Rivetti's characterization of the pharmacies as "dishonest" is notable. It reflects the DOJ's position, not a court finding, the settlement does not appear to include an admission of wrongdoing by Ahold Delhaize, though the DOJ has not clarified that point publicly.
The alleged fraud hinged on a gap between what customers paid and what the government was told they paid. Ahold Delhaize's pharmacies ran prescription savings programs, the kind of discount cards and membership benefits that grocery chains routinely advertise to draw foot traffic.
Those programs lowered the out-of-pocket cost for customers. But under federal rules, pharmacies must report the discounted price as the "usual and customary" price when billing Medicare Part D, Medicaid, and TRICARE. That price determines how much the government reimburses.
Instead, Ahold Delhaize's pharmacies allegedly submitted the higher, non-discounted price on their claims. The result: inflated reimbursements from three federal programs that together cover tens of millions of Americans, including seniors, low-income families, and active-duty military personnel and their dependents.
The DOJ did not disclose the time period over which the alleged conduct occurred, the total dollar amount of excess reimbursements, or which specific store banners were implicated. Those gaps leave open the question of whether the practice was concentrated in certain regions or spread across the company's entire pharmacy network.
LaBenne, the former pharmacist, is the reason this case exists. Whistleblower complaints like his are the engine behind a large share of federal healthcare fraud recoveries. The financial incentive is built into the system: whistleblowers who bring viable fraud claims can receive a percentage of whatever the government recovers.
In this case, LaBenne's share, more than $6 million, comes from the federal portion alone. The DOJ described the settlement as a coordinated effort involving the Health Department, the Defense Health Agency, and state Medicaid programs, suggesting multiple agencies had a hand in building the case after LaBenne's complaint set it in motion.
The DOJ's increasing willingness to pursue corporate billing fraud fits a broader pattern. The department has signaled a crackdown on food-industry pricing practices, and settlements of this kind send a message to companies that rely on federal healthcare dollars.
Several important questions remain unresolved. The DOJ has not disclosed the specific statute under which the claims were brought, though settlements of this type typically involve the False Claims Act. No case number or docket reference has been made public.
It is also unclear whether Ahold Delhaize admitted to any wrongdoing as part of the agreement, or whether the settlement is purely civil with no criminal referrals pending. The company has not been quoted in any public statement responding to the deal.
The healthcare billing world is rife with these disputes. Major insurers have faced their own multibillion-dollar settlements over anticompetitive conduct, and the federal government has grown more aggressive in policing the gap between what companies charge and what they report.
Nor is Ahold Delhaize the only large corporation to face federal enforcement over pricing transparency. The FTC and DOJ have both stepped up actions against companies accused of hiding the true cost of their products and services from consumers and government payers alike.
At its core, this case is about who bears the cost when a company games the billing system. Medicare Part D covers prescription drugs for seniors. Medicaid covers low-income Americans. TRICARE covers military families. All three are funded by taxpayers.
When a pharmacy reports a higher price than the one it actually charges, the excess comes out of federal program budgets, budgets already under strain. And when enforcement finally catches up, the settlement dollars flow back to the government, but the years of overpayment are never fully recovered. The $40 million figure is a negotiated resolution, not a full accounting of the alleged overcharges.
Federal scrutiny of food and grocery industry practices continues to expand. The DOJ has also prepared antitrust actions against major egg producers over alleged price coordination, part of a widening effort to hold food-supply companies accountable for practices that hit consumers and taxpayers in the wallet.
Forty million dollars sounds like a large number. For a company the size of Ahold Delhaize, it is a line item. For the taxpayers who funded the inflated reimbursements year after year, it is a reminder that the system trusts companies to report honestly, and that trust, once again, was misplaced.